, 2006) and a protein vaccine recombinant urease B (rUreB) based on the full-length urease B (Béguéet al., 2007). Our work showed that the DNA vaccine was not immunogenic, while rUreB was highly immunogenic, and that the prime-boost approach with either rUreB followed by the DNA vaccine or the reverse did not confer any additional benefit (Béguéet al., 2007). We also showed that rUreB was immunogenic when administered percutaneously but not by mucosal immunization, and that aluminum hydroxide significantly increased the immunogenicity of rUreB alone (Bégué & Moll, 2009). As aluminum hydroxide is an adjuvant accepted for use in human immunization, we then proceeded to evaluate the Palbociclib in vivo protective efficacy

of rUreB plus aluminum hydroxide against H. pylori infection and compared with other approaches we had found immunogenic. The this website results are reported here. rUreB was prepared as described previously (Béguéet al., 2007). Genomic H. pylori DNA (ATCC 43504D, Manassas, VA) was used as template to PCR-amplify the full-length ureB gene (GenBank AF352376; 1–1710 bp) and cloned into the SalI site of the pQE9 vector (Qiagen, Valencia,

CA). Competent XL10Gold E. coli cells were transformed and protein expression was induced with 1 mmol L−1 isopropyl-β-d-thiogalactopyranoside. Cells were lysed with 8 mol L−1 urea buffer (pH 8.0) and rUreB was purified by (His)6-tag affinity in a nickel column (Ni-NTA Superflow Column, Qiagen). The product was dialyzed to phosphate-buffered saline

(PBS, pH 7.4) and concentrated to 1 μg μL−1. Three different adjuvants were used in the experiment: CpG ODN 1826 (5′-tcc atg acg ttc ctg acg tt-3′) suspended in PBS to a concentration of 1 μg μL−1; aluminum hydroxide [Al(OH)3 3%, Alhydrogel, Brenntag Biosector, Frederikssund, Denmark] mixed with an equal volume of rUreB and incubated overnight at 4 °C for absorption; and Freund’s adjuvant (Sigma-Aldrich, St. Louis, MO), complete for first immunization and incomplete for subsequent ones. Six-week-old female BALB/c mice (Harlan Sprague, Dawley, Indianapolis, IN), Tolmetin five per group, were immunized either intranasally (40 μL rUreB plus 10 μL CpG), intramuscularly (50 μL rUreB plus 50 μL aluminum hydroxide) or subcutaneously (25 μL rUreB plus 25 μL Freund’s adjuvant) three times (weeks 0, 2 and 6). Control mice received no immunization. Before immunization and 2 weeks after the third dose, stool (two pellets) and blood (100 μL) were obtained from each animal to determine immunogenicity. Stools were suspended in 100 μL PBS, vortexed, centrifuged and the supernatant was collected; blood was centrifuged and serum was collected. Anti-urease B antibodies were determined by an enzyme-linked immunosorbent assay using rUreB expressed in Saccharomyces cerevisiae as the capture antigen (Béguéet al., 2007). Yeast-derived rUreB (0.